Ocular Therapeutix, Inc. (NASDAQ:OCUL)went down by -12.29% from its latest closing price when compared to the 1-year high value of $6.88 and move down -167.7%, while OCUL stocks collected -24.19% of loss with the last five trading sessions. Press Release reported 15 hours ago that Ocular Therapeutix(TM) Reports Third Quarter 2019 Financial Results and Business Update

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Worth an Investment?

Ocular Therapeutix, Inc. (NASDAQ: OCUL) The 36 Months beta value for OCUL stocks is at 2.07, while of the analysts out of 0 who provided ratings for Ocular Therapeutix, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $6.20 which is $4.23 above current price. OCUL currently has a short float of 16.31% and public float of 40.7M with average trading volume of 447.62K shares.

OCUL Market Performance

OCUL stocks went down by -24.19% for the week, with the monthly drop of -16.01% and a quarterly performance of -39.39%, while its annual performance rate touched -53.78%. The simple moving average for the period of the last 20 days is -23.33% for OCUL stocks with the simple moving average of -34.95% for the last 200 days.

Analysts’ Opinion on Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Many brokerage firms have already submitted their reports for OCUL stocks, with H.C. Wainwright repeating the rating for OCUL shares by setting it to “Buy”. The predicted price for OCUL socks in the upcoming period according to H.C. Wainwright is $9 based on the research report published on May 21, 2019.

Raymond James, on the other hand, stated in their research note that they expect to see OCUL stock at the price of $5, previously predicting the value of $11. The rating they have provided for OCUL stocks is “Outperform” according to the report published on May 21, 2019.

Cowen gave “ Market Perform” rating to OCUL stocks, setting the target price at $3 in the report published on May 21, 2019.

OCUL Stocks -28.17% Far from 50 Day Moving Average

After a stumble in the market that brought OCUL to its low price for the period of the last 52 weeks, Ocular Therapeutix, Inc. was unable to take a rebound, for now settling with -62.65% of loss for the given period.

The stock volatility was left at 8.05%, however, within the period of a single month, the volatility rate increased by 11.20%, while the shares sank at the distance of -22.12% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -38.81% lower at the present time.

In the course of the last 5 trading sessions, OCUL went down by -24.19%, which changed the moving average for the period of 200 days to the total of -32.72% of losses for the stock in comparison to the 20-day moving average settled at $3.32. In addition, Ocular Therapeutix, Inc. saw -35.43% in overturn over the period of a single year with a tendency to cut further losses.

OCUL Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at Ocular Therapeutix, Inc. (OCUL), starting from Williams Leslie J., who bought 4,500 shares at the price of $4.40 back on Jun 14. After this action, Rushing now owns 4,500 shares of Ocular Therapeutix, Inc., valued at $19,800 with the latest closing price.

Notman Donald, the Chief Financial Officer of Ocular Therapeutix, Inc., bought 2,500 shares at the value of $4.33 during a trade that took place back on Jun 14, which means that Notman Donald is holding 24,049 shares at the value of $10,825 based on the most recent closing price.

OCUL Stock Fundamentals

The current profitability levels are settled at -2970.75 for the present operating margin and -38.24 for gross margin. The net margin for Ocular Therapeutix, Inc. stands at -3013.97. Total capital return value is set at -112.79, while invested capital returns managed to touch -120.82. Equity return holds the value -256.70%, with -88.50% for asset returns.

Based on Ocular Therapeutix, Inc. (OCUL), the company’s capital structure generated 69.10 points for debt to equity in total, while total debt to capital is set at the value of 40.86. Total debt to assets is settled at the value of 33.94 with long-term debt to equity ratio rests at -34.00 and long-term debt to capital is 69.10.

The value for Enterprise to Sales is 59.43 with debt to enterprise value settled at 0.20. The receivables turnover for Ocular Therapeutix, Inc. is 9.32 with the total asset turnover at the value of 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.14.